XBiotech Inc. (XBIT)’s Financial Results Comparing With Intrexon Corporation (NASDAQ:XON)

Since XBiotech Inc. (NASDAQ:XBIT) and Intrexon Corporation (NASDAQ:XON) are part of the Biotechnology industry, they are influenced by contrast. The influences particularly affect the analyst recommendations, profitability, institutional ownership, risk, dividends, earnings and valuation of both companies.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
XBiotech Inc. N/A 0.00 22.28M -0.65 0.00
Intrexon Corporation 160.57M 5.62 509.34M -0.81 0.00

Table 1 showcases the top-line revenue, earnings per share and valuation of XBiotech Inc. and Intrexon Corporation.


Table 2 demonstrates the net margins, return on equity and return on assets of XBiotech Inc. and Intrexon Corporation.

Net Margins Return on Equity Return on Assets
XBiotech Inc. 0.00% -41.4% -39.5%
Intrexon Corporation -317.21% -35% -22.1%

Volatility & Risk

XBiotech Inc. is 69.00% less volatile than Standard and Poor’s 500 due to its 0.31 beta. Competitively, Intrexon Corporation’s 138.00% volatility makes it more volatile than Standard and Poor’s 500, because of the 2.38 beta.


9.3 and 9.3 are the respective Current Ratio and a Quick Ratio of XBiotech Inc. Its rival Intrexon Corporation’s Current and Quick Ratios are 3.4 and 3.2 respectively. XBiotech Inc. has a better chance of clearing its pay short and long-term debts than Intrexon Corporation.

Insider and Institutional Ownership

Roughly 13.2% of XBiotech Inc. shares are held by institutional investors while 86.7% of Intrexon Corporation are owned by institutional investors. About 37.5% of XBiotech Inc.’s share are held by insiders. Comparatively, insiders own roughly 0.6% of Intrexon Corporation’s shares.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
XBiotech Inc. 13.76% 40.3% 121% 137.44% 90.53% 82.28%
Intrexon Corporation -51.18% -45.95% -57.36% -73.55% -67.91% -36.7%

For the past year XBiotech Inc. had bullish trend while Intrexon Corporation had bearish trend.


XBiotech Inc. beats Intrexon Corporation on 5 of the 9 factors.

XBiotech Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases. The companyÂ’s lead product is Xilonix, which is also known as MABp1, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer. It has also investigating its lead product candidate in various clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum, and hidradenitis suppurativa, as well as staphylococcus aureus infection, influenza, and clostridium difficile infection diseases. XBiotech, Inc. was founded in 2005 and is headquartered in Austin, Texas.

Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics platform. It also provides reproductive technologies and other genetic processes to cattle breeders and producers; genetic preservation and cloning technologies; genetically engineered swine for medical and genetic research; biological insect control solutions; technologies for non-browning apple without the use of any flavor-altering chemical or antioxidant additives; commercial aquaculture products; and artwork, children's toys, and novelty goods that are derived from living organisms or enabled by synthetic biology. The company serves health, food, energy, environment, and consumer sectors. Intrexon Corporation has collaboration and license agreements with Ares Trading S.A.; ZIOPHARM Oncology, Inc.; Oragenics, Inc.; Fibrocell Science, Inc.; Genopaver, LLC; S & I Ophthalmic, LLC; OvaXon, LLC; Intrexon Energy Partners, LLC; Persea Bio, LLC; Thrive Agrobiotics, Inc.; Intrexon Energy Partners II, LLC; and others. The company was formerly known as Genomatix Ltd. and changed its name to Intrexon Corporation in 2005. Intrexon Corporation was founded in 1998 and is based in Germantown, Maryland.